This inventor holds 1 USPTO granted patent. Top assignee: Emory University. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Christopher Dalloul: Innovator in Neurodegenerative Disease Treatment
Introduction
Christopher Dalloul is a notable inventor based in Terre Haute, IN (US). He has made significant contributions to the field of neurodegenerative diseases through his innovative research and patent work. His dedication to improving treatment options for conditions such as Parkinson's and Alzheimer's diseases has positioned him as a key figure in medical research.
Latest Patents
Dalloul holds a patent for "Abelson non-tyrosine kinase compounds for the treatment of neurodegenerative diseases." This patent focuses on compounds that target the Abelson non-tyrosine kinase (c-Abl) protein, which plays a crucial role in treating various neurological disorders. The patent outlines pharmaceutical compositions and methods for treating these conditions, highlighting Dalloul's commitment to advancing medical science.
Career Highlights
Christopher Dalloul is affiliated with Emory University, where he conducts research and collaborates with other experts in the field. His work has led to the development of innovative treatments that aim to alleviate the symptoms of debilitating neurological diseases. Dalloul's research is characterized by a strong focus on the underlying mechanisms of these disorders, which has the potential to lead to groundbreaking therapies.
Collaborations
Dalloul has worked alongside notable colleagues such as Thomas Kaiser and Zackery Will Dentmon. These collaborations have enriched his research and contributed to the advancement of knowledge in the treatment of neurodegenerative diseases.
Conclusion
Christopher Dalloul's contributions to the field of neurodegenerative disease treatment through his patent and research at Emory University demonstrate his commitment to improving patient outcomes. His innovative work continues to inspire advancements in medical science.